Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

423803

registered interest
date	26/10/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	NHS Protect
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, how many investigation NHS Protect have commenced into directors of NHS Trusts (a) nationally and (b) in Yorkshire in the last 18 months; and how many of those investigations are ongoing.
tabling member constituency	Kingston upon Hull North
tabling member printed	Diana Johnson
uin	13485
answer	answer is ministerial correction date of answer 29/10/2015 answer text <p>In the last 18 months NHS Protect has commenced three investigations into directors of National Health Service trusts. All three investigations are ongoing and further information cannot be given at this time.</p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 29/10/2015 17:29:11 answering member 4020 label Biography information for George Freeman
tabling member	1533 label Biography information for Dame Diana Johnson

423804

registered interest
date	26/10/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	NHS Protect
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what the average time is for NHS Protect to complete an investigation.
tabling member constituency	Kingston upon Hull North
tabling member printed	Diana Johnson
uin	13484
answer	answer is ministerial correction date of answer 29/10/2015 answer text <p>This information is not held centrally and could only be obtained at disproportionate cost.</p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 29/10/2015 17:30:23 answering member 4020 label Biography information for George Freeman
tabling member	1533 label Biography information for Dame Diana Johnson

423864

registered interest
date	26/10/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Crohn's Disease
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what progress has been made on tackling Crohn's disease.
tabling member constituency	South Suffolk
tabling member printed	James Cartlidge
uin	13375
answer	answer is ministerial correction date of answer 29/10/2015 answer text <br /><p>Information is not collected centrally on the number of people prescribed medicines or the medical condition being treated.</p><br /><p>Some data is available for the administration of vedolizumab however this data does not correspond to patient numbers nor can it be linked to the treatment of specific diseases. Some information on cost is also available but this is the cost of the medicines at NHS list price and not necessarily the price that hospitals paid.</p><br /><p>In guidance published in August 2015, the National Institute for Health and Care Excellence (NICE) advised that vedolizumab is the recommended treatment for adults with moderate to severe Crohn’s disease if a type of treatment called a tumour necrosis factor alpha inhibitor is not suitable or has not worked well enough. NICE also recommend vedolizumab as a possible treatment for adults with moderate to severe ulcerative colitis in separate guidance published on 5 June 2015.</p><br /><p>In both cases, people should be able to have vedolizumab until it stops working, or surgery is needed, or for 12 months after starting it, whichever is shorter. Their condition should be assessed 12 months after they started taking vedolizumab. If they still have symptoms but it is clear that the treatment is helping, they can continue to have the drug. If they no longer have symptoms, treatment can be stopped, and later restarted if their symptoms return. Drugs recommended by NICE should be available on the NHS within three months of the technology appraisal guidance being issued.</p><br /><p>NICE has set out best practice in the diagnosis, treatment care and support of patients with Crohn’s diseases and ulcerative colitis in its guidance <em>Crohn’s Disease Management in Adults, Children and Young People</em> in October 2012, and <em>Ulcerative Colitis</em> <em>Management in Adults, Children and Young People</em> , published in June 2013. Treatment for both Crohn’s disease and ulcerative colitis is largely directed at symptom relief to improve quality of life, rather than cure. Management options include drug therapy, dietary and lifestyle advice and, in severe or chronic active disease, surgery.</p><br /> answering member constituency Mid Norfolk answering member printed George Freeman grouped question UIN 13299 13300 question first answered 29/10/2015 17:23:06 answering member 4020 label Biography information for George Freeman
tabling member	4519 label Biography information for James Cartlidge

423943

registered interest
date	26/10/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Inflammatory Bowel Disease: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what estimate his Department has made of the number of people with both ulcerative colitis and Crohn's disease who have benefitted from the use of vedolizumab as a treatment option since February 2015; and what the cost of this treatment has been in that period.
tabling member constituency	Brigg and Goole
tabling member printed	Andrew Percy
uin	13299
answer	answer is ministerial correction date of answer 29/10/2015 answer text <br /><p>Information is not collected centrally on the number of people prescribed medicines or the medical condition being treated.</p><br /><p>Some data is available for the administration of vedolizumab however this data does not correspond to patient numbers nor can it be linked to the treatment of specific diseases. Some information on cost is also available but this is the cost of the medicines at NHS list price and not necessarily the price that hospitals paid.</p><br /><p>In guidance published in August 2015, the National Institute for Health and Care Excellence (NICE) advised that vedolizumab is the recommended treatment for adults with moderate to severe Crohn’s disease if a type of treatment called a tumour necrosis factor alpha inhibitor is not suitable or has not worked well enough. NICE also recommend vedolizumab as a possible treatment for adults with moderate to severe ulcerative colitis in separate guidance published on 5 June 2015.</p><br /><p>In both cases, people should be able to have vedolizumab until it stops working, or surgery is needed, or for 12 months after starting it, whichever is shorter. Their condition should be assessed 12 months after they started taking vedolizumab. If they still have symptoms but it is clear that the treatment is helping, they can continue to have the drug. If they no longer have symptoms, treatment can be stopped, and later restarted if their symptoms return. Drugs recommended by NICE should be available on the NHS within three months of the technology appraisal guidance being issued.</p><br /><p>NICE has set out best practice in the diagnosis, treatment care and support of patients with Crohn’s diseases and ulcerative colitis in its guidance <em>Crohn’s Disease Management in Adults, Children and Young People</em> in October 2012, and <em>Ulcerative Colitis</em> <em>Management in Adults, Children and Young People</em> , published in June 2013. Treatment for both Crohn’s disease and ulcerative colitis is largely directed at symptom relief to improve quality of life, rather than cure. Management options include drug therapy, dietary and lifestyle advice and, in severe or chronic active disease, surgery.</p><br /> answering member constituency Mid Norfolk answering member printed George Freeman grouped question UIN 13300 13375 question first answered 29/10/2015 17:23:06 answering member 4020 label Biography information for George Freeman
tabling member	3939 label Biography information for Andrew Percy

423944

registered interest
date	26/10/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Crohn's Disease: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what recent assessment his Department has made of the effectiveness of vedolizumab as a treatment for Crohn's disease.
tabling member constituency	Brigg and Goole
tabling member printed	Andrew Percy
uin	13300
answer	answer is ministerial correction date of answer 29/10/2015 answer text <br /><p>Information is not collected centrally on the number of people prescribed medicines or the medical condition being treated.</p><br /><p>Some data is available for the administration of vedolizumab however this data does not correspond to patient numbers nor can it be linked to the treatment of specific diseases. Some information on cost is also available but this is the cost of the medicines at NHS list price and not necessarily the price that hospitals paid.</p><br /><p>In guidance published in August 2015, the National Institute for Health and Care Excellence (NICE) advised that vedolizumab is the recommended treatment for adults with moderate to severe Crohn’s disease if a type of treatment called a tumour necrosis factor alpha inhibitor is not suitable or has not worked well enough. NICE also recommend vedolizumab as a possible treatment for adults with moderate to severe ulcerative colitis in separate guidance published on 5 June 2015.</p><br /><p>In both cases, people should be able to have vedolizumab until it stops working, or surgery is needed, or for 12 months after starting it, whichever is shorter. Their condition should be assessed 12 months after they started taking vedolizumab. If they still have symptoms but it is clear that the treatment is helping, they can continue to have the drug. If they no longer have symptoms, treatment can be stopped, and later restarted if their symptoms return. Drugs recommended by NICE should be available on the NHS within three months of the technology appraisal guidance being issued.</p><br /><p>NICE has set out best practice in the diagnosis, treatment care and support of patients with Crohn’s diseases and ulcerative colitis in its guidance <em>Crohn’s Disease Management in Adults, Children and Young People</em> in October 2012, and <em>Ulcerative Colitis</em> <em>Management in Adults, Children and Young People</em> , published in June 2013. Treatment for both Crohn’s disease and ulcerative colitis is largely directed at symptom relief to improve quality of life, rather than cure. Management options include drug therapy, dietary and lifestyle advice and, in severe or chronic active disease, surgery.</p><br /> answering member constituency Mid Norfolk answering member printed George Freeman grouped question UIN 13299 13375 question first answered 29/10/2015 17:23:06 answering member 4020 label Biography information for George Freeman
tabling member	3939 label Biography information for Andrew Percy

423952

registered interest
date	26/10/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Cancer: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what recent assessment he has made of the effectiveness of the (a) Bendamustine and (b) Ibrutinib drugs in treating cancer; and if he will make a statement.
tabling member constituency	Tewkesbury
tabling member printed	Mr Laurence Robertson
uin	13444
answer	answer is ministerial correction date of answer 29/10/2015 answer text <p>The National Institute for Health and Care Excellence (NICE) is the independent body which makes decisions on the clinical and cost effectiveness of products based on a thorough assessment of the best available evidence and in consultation with stakeholders. National Health Service commissioners are required to fund drugs and treatments recommended by NICE technology appraisals.</p><br /><p>Bendamustine (Levact) is recommended by NICE as a possible treatment for some people with chronic lymphocytic leukaemia of Binet stage B or C.</p><br /><p>NICE is currently appraising ibrutinib (Imbruvica) for the treatment of (i) chronic lymphocytic leukaemia (NICE’s final guidance is expected in June 2016) and (ii) mantle cell, relapsed, refractory lymphoma (NICE’s final guidance is expected in December 2016).</p><br /> <br /> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 29/10/2015 17:31:39 answering member 4020 label Biography information for George Freeman
tabling member	253 label Biography information for Mr Laurence Robertson

423341

registered interest
date	22/10/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Drugs: Licensing
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, whether addressing barriers to licensing off-patent, repurposed drugs in an aim of the current Accelerated Access Review.
tabling member constituency	Tewkesbury
tabling member printed	Mr Laurence Robertson
uin	13134
answer	answer is ministerial correction date of answer 27/10/2015 answer text <p>The Accelerated Access Review, chaired by Sir Hugh Taylor, will make recommendations to government on reforms to accelerate access for National Health Service patients to innovative medicines and medical technologies (including devices, diagnostics and digital), making our country the best place in the world to design, develop and deploy these products. This will cover products that may already be on the market and off patent but are being innovatively repurposed to treat conditions other than those in remit of the existing license.</p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 27/10/2015 15:50:14 answering member 4020 label Biography information for George Freeman
tabling member	253 label Biography information for Mr Laurence Robertson

423349

registered interest
date	22/10/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Breast Cancer
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, pursuant to the Answer of 21 October 2015 to Question 12247, on breast cancer, what assessment his Department has made of the 26 recommendations produced by charities on access to off-patent, repurposed drugs following the roundtable event of February 2015.
tabling member constituency	Tewkesbury
tabling member printed	Mr Laurence Robertson
uin	13077
answer	answer is ministerial correction date of answer 27/10/2015 answer text <p>The Government hosted a Roundtable Event to explore the issues around off-label prescribing as part of its response to a Private Member’s Bill presented in the last Parliament. The Government’s position on the current Off Patent Drugs Bill and how that relates to issues identified at the Roundtable Event will be shared at the Bill’s second reading on 6 November 2015.</p><br /> <br /><p><strong></strong></p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 27/10/2015 15:51:52 answering member 4020 label Biography information for George Freeman
tabling member	253 label Biography information for Mr Laurence Robertson

423360

registered interest
date	22/10/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Breast Cancer: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what steps he has taken to make bisphosphonates routinely available on the NHS to prevent the spread of breast cancer to bones.
tabling member constituency	Tewkesbury
tabling member printed	Mr Laurence Robertson
uin	12952
answer	answer is ministerial correction date of answer 27/10/2015 answer text <p>Where there is a clinical need to do so for a patient, clinicians are legally able to prescribe bisphosphonates for breast cancer prevention.</p><br /><p>NHS England’s Breast Cancer Clinical Reference Group (CRG) has included the use of bisphosphonates in their draft service guidance for breast cancer. The CRG has highlighted bisphosphonates as a key issue for potential improvement in survival outcomes.</p><br /><p>NHS England expects the draft service guidance to be finalised and available for dissemination in the autumn of 2015. It will then be up to clinical commissioning groups to consider how they adopt this in to their local commissioning activities.</p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 27/10/2015 15:51:16 answering member 4020 label Biography information for George Freeman
tabling member	253 label Biography information for Mr Laurence Robertson

422970

registered interest
date	21/10/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	General Practitioners: Databases
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, pursuant to the Answer of 23 July 2015 to Question 7630, how many GP practices in each pathfinder area have signed up to care.data to date in total.
tabling member constituency	Copeland
tabling member printed	Mr Jamie Reed
uin	12767
answer	answer is ministerial correction date of answer 29/10/2015 answer text <br /> <br /><p>The information requested is provided in the following table:</p><p><strong></strong></p><table><tbody><tr><td><p>Pathfinder clinical commissioning groups.</p></td><td><p>GP Practices</p></td></tr><tr><td><p>Blackburn with Darwen</p></td><td><p>23</p></td></tr><tr><td><p>Leeds</p></td><td><p>15</p></td></tr><tr><td><p>West Hampshire</p></td><td><p>30</p></td></tr><tr><td><p>Somerset</p></td><td><p>56</p></td></tr></tbody></table><p><strong></strong></p><p><strong></strong></p><p><strong></strong></p><p><strong></strong></p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 29/10/2015 17:11:25 answering member 4020 label Biography information for George Freeman
tabling member	1503 label Biography information for Mr Jamie Reed